Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | IDE | P14735 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RIN1 | Q13671 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | HLCS | P50747 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL13272362 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8763 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL14489489 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL38817 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL16897730 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20547409 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL5690544 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217986-A1 | METHOD OF PRODUCING HYDROXYTHIENOIMIDAZOLE DERIVATIVE, VINYL SULFIDE DERIVATIVE, N-BUTYLIDENE SULFIDE DERIVATIVE, AND THIENOIMIDAZOLE DERIVATIVE SUBSTITUTED WITH STRAIGHT-CHAIN SATURATED HYDROCARBON | TOKUYAMA CORPORATION (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20230183260-A1 | FULL CONTINUOUS-FLOW PREPARATION METHOD OF (+)-BIOTIN | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| US-10689349-B2 | Method for producing intermediate of biotin and method for producing biotin | TOKUYAMA CORPORATION (JP) | 2020-06-23 | — | — | US | disclosed |
| US-9670255-B2 | Modified biotin, mutant streptavidin, and use thereof | SAVID THERAPEUTICS INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9670255-B2 | Modified biotin, mutant streptavidin, and use thereof | SAVID THERAPEUTICS INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160137704-A1 | MODIFIED BIOTIN, MUTANT STREPTAVIDIN, AND USE THEREOF | SAVID THERAPEUTICS INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-9089605-B2 | Quinone derivatives, pharmaceutical compositions, and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2721044-A1 | SYNTHETIC PENTASACCHARIDES HAVING SHORT HALF-LIFE AND HIGH ACTIVITY | Carbomimetics (FR) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012172104-A1 | SYNTHETIC PENTASACCHARIDES HAVING SHORT HALF-LIFE AND HIGH ACTIVITY | ENDOTIS PHARMA (FR) | 2012-12-20 | — | — | WO | disclosed |
| US-20120083599-A1 | Biomolecular Labelling Using Multifunctional Biotin Analogues | UNIVERSITY OF NOTTINGHAM (GB) | 2012-04-05 | — | — | US | disclosed |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2010-11-25 | — | — | US | disclosed |
| US-7598092-B2 | Methods, devices, systems and computer program products for stochastic, competitive, force-based analyte detection | TOONE ERIC | 2009-10-06 | — | — | US | disclosed |
| US-20080090259-A1 | METHODS, DEVICES, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR STOCHASTIC, COMPETITIVE, FORCE-BASED ANALYTE DETECTION | TOONE ERIC | 2008-04-17 | — | — | US | disclosed |
| EP-1322619-B1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7172877-B2 | Methods and compositions for peptide and protein labeling | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689349-B2 | Method for producing intermediate of biotin and method for producing biotin | BRSK1, BTD, RBCK1 | TDP1 4818/4885MEN1 701/4885ABL1 2535/4885 |
| US-20120083599-A1 | Biomolecular Labelling Using Multifunctional Biotin Analogues | BTD, URB2, RAET1L | TDP1 4767/4885MEN1 3602/4885ABL1 2957/4885 |
| US-20230183260-A1 | FULL CONTINUOUS-FLOW PREPARATION METHOD OF (+)-BIOTIN | BTD, DECR1, GABRA1 | TDP1 4361/4885MEN1 2378/4885ABL1 2860/4885 |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | APEX1, NQO1, REV1 | TDP1 118/4885MEN1 2751/4885ABL1 2541/4885 |
| US-20160137704-A1 | MODIFIED BIOTIN, MUTANT STREPTAVIDIN, AND USE THEREOF | BTD, HLCS, BSG | TDP1 3582/4885MEN1 1987/4885ABL1 1238/4885 |
| US-20240217986-A1 | METHOD OF PRODUCING HYDROXYTHIENOIMIDAZOLE DERIVATIVE, VINYL SULFIDE DERIVATIVE, N-BUTYLIDENE SULFIDE DERIVATIVE, AND THIENOIMIDAZOLE DERIVATIVE SUBSTITUTED WITH STRAIGHT-CHAIN SATURATED HYDROCARBON | TST, SHH, BHMT2 | TDP1 4722/4885MEN1 2321/4885ABL1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.